BIA welcomes the release of the AMR Industry Alliance’s first progress report

The BIA today welcomes the release of the AMR Industry Alliance’s first progress report assessing the action being taken to tackle antimicrobial resistance.

The AMR Industry Alliance is a coalition of over 100 biotechnology, diagnostic, generics and research-based biopharmaceutical companies and trade associations that was formed to drive and measure industry progress to tackle antimicrobial resistance. The AMR Industry Alliance ensures that signatories collectively deliver on the specific commitments made in the Industry Declaration on AMR and the Roadmap and measures progress made in the fight against antimicrobial resistance.

Highlights from the report include data showing that 22 Alliance companies invested at least $2bn in R&D dedicated to AMR-related products in 2016. In addition, two out of three Alliance companies surveyed with marketed AMR products have strategies, policies or plans in place to improve access to their AMR-relevant products.

Welcoming the report, BIA CEO and Vice-Chair of the International Confederation of Biotech Associations (ICBA) Steve Bates said:

“It is fantastic to see the steps that industry has taken to tackle one of the world’s most pressing public health challenges. There is a great deal of promising science being undertaken in the UK on AMR, but a lack of pull incentives is still preventing significant venture capital investment. This barrier must be removed to enable biotech companies to do more in this field. I hope to see movement from policymakers in this area in 2018.”  

This first progress report has aggregated data from 36 companies from all four categories represented in the Alliance: all research-based biopharmaceutical companies (11 out of 11), half of the generics (3 out of 6), one third of diagnostics members (5 out of 15), and one quarter (17 out of 68) of SMEs provided input. The Alliance is committed to reporting progress every two years. It is also dedicated to refining its approach to better address the challenges for its members in responding, so that it can achieve greater participation than seen in this first report.

BIA CEO and Vice-Chair of the International Confederation of Biotech Associations (ICBA) Steve Bates spoke at Chatham House in London and gave his insight into the pioneering science being done by UK biotech companies in the AMR space, such as Destiny Pharma, the AMR Centre, and BIA members Novabiotics and Summit.

 

 

 

 

 

 

 

 

Ends

Notes to Editors

Contact: Ed Sexton, BIA Communications and Media Relations Manager: esexton@bioindustry.org  or call 0207 630 2196

 

About the AMR Industry Alliance

The AMR Industry Alliance is a coalition of over 100 biotechnology, diagnostic, generics and research-based biopharmaceutical companies and trade associations that was formed to drive and measure industry progress to curb antimicrobial resistance. The AMR Industry Alliance ensures that signatories collectively deliver on the specific commitments made in the Industry Declaration on AMR and the Roadmap and measures progress made in the fight against antimicrobial resistance.

 

About the UK BioIndustry Association (BIA)

Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.

For further information, please go to www.bioindustry.org and twitter.com/BIA_UK.